Welcome to our dedicated page for iTonic Holdings SEC filings (Ticker: ITOC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
iTonic Holdings Ltd filings document foreign-issuer current reports on its brachytherapy healthcare-solutions business, corporate events and listed-company status. The company's Form 6-K disclosures include press-release exhibits, Nasdaq minimum bid price compliance matters, and descriptions of its operating subsidiary, Beijing Feitian Zhaoye Technology Co., Ltd., and lead treatment-planning product.
The filing record also covers material-event disclosures, material agreements, capital-structure matters, governance topics, and operating and financial results. These disclosures connect the company's public reporting to its Class A ordinary shares, healthcare-technology operations and corporate obligations as a listed issuer.
iTonic Holdings Ltd (symbol ITOC) announced that on August 27, 2026, Chief Financial Officer Zhixin Li resigned effective immediately. Ms. Li confirmed her resignation was not due to any disagreement with the company, its management or board, and that she has no claims against the company or its stakeholders.
On the same date, the board appointed Simin Tan as Chief Financial Officer. The company entered into an employment agreement and an indemnification agreement with Ms. Tan, filed as Exhibits 10.1 and 10.2. The company states there are no related-party transactions involving Ms. Tan requiring disclosure under Item 7.B of Form 20-F. Ms. Tan, age 31, has prior audit and tax experience with MarcumAsia CPAs LLP, PwC China, DAHUA CPA Firm, and Pattillo, Brown & Hill, LLP, and holds bachelor’s and master’s degrees from Baylor University. The contents of this report are incorporated by reference into iTonic’s existing Form S-8 and Form F-3 registration statements.
iTonic Holdings Ltd (ITOC) has called an extraordinary general meeting on September 9, 2026 (Hong Kong time), to be held virtually, for shareholders of record at the close of business on August 19, 2026.
Shareholders will vote on a 1-for-16 Share Consolidation of both Class A and Class B ordinary shares, effective 12:01 a.m. Eastern Time on October 6, 2026, subject to timely Nasdaq notification and Nasdaq not objecting. Fractional shares will not be issued and will instead be rounded up to the next whole share. Following the consolidation, an ordinary resolution would increase authorised share capital from US$50,000 to US$800,000, by creating additional Class A and Class B shares at the higher par value. A special resolution would adopt a Fourth Amended and Restated Memorandum and Articles of Association to reflect these changes and update provisions on share consolidation, quorum (at least one-third of voting rights) and notice. A further resolution would revoke prior share-consolidation authority granted on December 19, 2025.
iTonic Holdings Ltd reported a board change, with independent director Bin Wu resigning effective June 18, 2026, for personal reasons and without any disagreement over operations, policies, or practices. On the same date, Kun Yang was appointed as a new independent director and joined the Audit, Corporate Governance and Nominating, and Compensation Committees, becoming chair of the Corporate Governance and Nominating Committee. The company notes that Kun Yang meets Nasdaq and SEC independence requirements and has entered into a director agreement and an indemnification agreement with the company.
iTonic Holdings Ltd completed a new private share sale to bring in fresh capital. After mutually terminating a prior March 2026 subscription agreement, the company entered into new Subscription Agreements on April 16, 2026 for a private placement of 100,000,000 Class A ordinary shares at US$0.20 per share, for aggregate gross proceeds of approximately US$20,000,000.
The April 2026 private placement closed the same day, and iTonic issued 100,000,000 Class A ordinary shares to participating investors. These new shares are subject to a six-month lock-up period from the date of issuance, limiting immediate resale. The report also states that its contents are incorporated by reference into the company’s existing Form S-8 and Form F-3 registration statements.
iTonic Holdings Ltd received a 180-day extension from Nasdaq, until October 19, 2026, to regain compliance with Nasdaq’s minimum closing bid price requirement under Listing Rule 5550(a)(2). The company previously exhausted an initial 180-day compliance period that ended on April 20, 2026.
If iTonic does not meet the minimum bid price rule by the new deadline, Nasdaq may delist its Class A ordinary shares. iTonic could then request a review of any delisting determination by a Nasdaq Hearings Panel. The company continues to describe itself as a healthcare solution provider focused on brachytherapy treatment planning systems.